OKYO Pharma's CEO Gary Jacob says they're expecting to file an Investigational New Drug Application (IND) in Q3 next year for its lead pre-clinical compound OK-101 in the treatment of dry eye disease. He says they're also anticipating to commence human studies with a Phase 2 clinical trial in DED patients in Q4 2022.
OKYO Pharma to take its dry eye treatment directly into phase 2 study
